Needham & Company LLC Reiterates “Hold” Rating for Omeros (NASDAQ:OMER)

Omeros (NASDAQ:OMER)‘s stock had its “hold” rating reissued by equities research analysts at Needham & Company LLC in a research report issued to clients and investors on Tuesday,Benzinga reports.

Several other research firms have also commented on OMER. StockNews.com lowered shares of Omeros from a “hold” rating to a “sell” rating in a research report on Friday, March 21st. D. Boral Capital reissued a “buy” rating and set a $36.00 target price on shares of Omeros in a research report on Tuesday. One research analyst has rated the stock with a sell rating, two have issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Trading Up 1.4 %

Shares of OMER traded up $0.12 during mid-day trading on Tuesday, hitting $8.34. The company’s stock had a trading volume of 534,664 shares, compared to its average volume of 540,716. The company’s 50-day moving average is $8.66 and its 200-day moving average is $7.58. Omeros has a 52-week low of $2.61 and a 52-week high of $13.60. The firm has a market capitalization of $483.01 million, a price-to-earnings ratio of -3.60 and a beta of 2.03.

Hedge Funds Weigh In On Omeros

Hedge funds have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Omeros by 3.6% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,831 shares of the biopharmaceutical company’s stock worth $314,000 after purchasing an additional 1,110 shares during the last quarter. Truvestments Capital LLC lifted its stake in shares of Omeros by 116.5% during the fourth quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 1,669 shares during the period. Tower Research Capital LLC TRC grew its holdings in shares of Omeros by 79.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 1,972 shares during the last quarter. Ameriprise Financial Inc. increased its position in shares of Omeros by 2.0% in the 4th quarter. Ameriprise Financial Inc. now owns 120,493 shares of the biopharmaceutical company’s stock valued at $1,190,000 after acquiring an additional 2,317 shares during the period. Finally, Cerity Partners LLC raised its stake in Omeros by 9.9% in the 4th quarter. Cerity Partners LLC now owns 28,989 shares of the biopharmaceutical company’s stock worth $286,000 after acquiring an additional 2,600 shares during the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.